MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Chemotherapy

Heparanase inhibitors restrain mesothelioma.

Oncotarget 2018 December 7 [Link] Lapidot M1, Barash U1, Vlodavsky I1, Pass H2. Abstract Malignant mesothelioma is a highly aggressive form of cancer with poor prognosis due to lack of markers for early diagnosis and resistance to conventional therapies. Heparanase, the sole heparan sulfate (HS) degrading endoglycosidase, regulates multiple biological activities that enhance tumor growth, metastasis, angiogenesis, and inflammation. Heparanase accomplishes this […]

Comments Off on Heparanase inhibitors restrain mesothelioma.

Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort.

F1000Research 2018 August 3 [Link] Amin W, Linkov F, Landsittel DP, Silverstein JC, Becich MJ Abstract Background: Malignant mesothelioma (MM) is a rare but deadly malignancy with about 3,000 new cases being diagnosed each year in the US. Very few studies have been performed to analyze factors associated with mesothelioma survival, especially for peritoneal presentation. […]

Comments Off on Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort.

Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases.

Clinical Lung Cancer 2018 November 29 [Link] McGehee E, Gerber DE, Reisch J, Dowell JE Abstract Primary pericardial mesothelioma (PPM) is a rare cancer for which there is no consensus on treatment. We evaluated and summarized a large contemporary population of published PPM cases to characterize risk factors, treatment patterns, and clinical outcomes. Using Ovid […]

Comments Off on Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases.

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.

EBioMedicine 2018 December 20 [Link] Sciarrillo R1, Wojtuszkiewicz A2, El Hassouni B, Funel N, Gandellini P, Lagerweij T, Buonamici S, Blijlevens M, Zeeuw van der Laan EA, Zaffaroni N, Deraco M, Kusamura S, Würdinger T, Peters GJ, Molthoff CFM, Jansen G, Kaspers GJL, Cloos J, Giovannetti E Abstract INTRODUCTION: Therapeutic options for diffuse malignant peritoneal […]

Comments Off on Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.

The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma.

Journal of Clinical Pharmacy and Therapeutics 2018 December 2018 [Link] Mense ES, Smit AAJ, Crul M, Franssen EJF Abstract WHAT IS KNOWN AND OBJECTIVE: The use of cisplatin in the treatment of lung carcinoma is limited by nephrotoxicity. The aim of this study was to determine whether the incidence of nephrotoxicity in patients with lung […]

Comments Off on The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma.

Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma.

Journal of Thoracic and Cardiovascular Surgery 2019 January [Link] Hashimoto M, Takeuchi J, Takuwa T, Kuroda A, Nakamura A, Nakamichi T, Matsumoto S, Kondo N, Nakano T, Morimoto T, Hasegawa S Abstract OBJECTIVES: Definitive diagnosis of the T-component is sometimes challenging in malignant pleural mesothelioma (MPM). Pleural thickness has been reported to be a prognostic […]

Comments Off on Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma.

Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft.

Molecules 2018 November 29 [Link] Izquierdo-Sánchez V, Muñiz-Hernández S, Vázquez-Becerra H, Pacheco-Yepez J, Romero-Piña ME, Arrieta O, Medina LA Abstract Malignant pleural mesothelioma (MPM) is the most common tumor of the pulmonary pleura. It is a rare and aggressive malignancy, generally associated with continuous occupational exposure to asbestos. Only a multimodal-approach to treatment, based on […]

Comments Off on Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft.

Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.

The Journal of Thoracic and Cardiovascular Surgery 2018 October 22 [] Verma V, Ahern CA, Berlind CG, Lindsay WD, Grover S, Friedberg JS, Simone CB Abstract OBJECTIVES: There are 2 main treatment paradigms recognized by the National Comprehensive Cancer Network for resectable malignant pleural mesothelioma (MPM): induction chemotherapy followed by resection (IC/R), and up-front resection […]

Comments Off on Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.

A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205).

Translational Lung Cancer Research 2018 October [Link] Raskin J, Surmont V, Cornelissen R, Baas P, van Schil PEY, van Meerbeeck JP Abstract Radical multimodality treatment for malignant pleural mesothelioma (MPM) is controversial, with intense debate (but lack of data) about which surgical procedure to perform [extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD)], if any. In order […]

Comments Off on A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205).

Update on the management of malignant peritoneal mesothelioma.

Translational Lung Cancer Research 2018 October [Link] Sugarbaker PH Abstract Malignant peritoneal mesothelioma (MPM) is a rare disease whose natural history is confined to the peritoneal space. Systemic chemotherapy has little impact on survival of patients with MPM. A surgical procedure with a goal of resection of all visible evidence of disease, called cytoreductive surgery […]

Comments Off on Update on the management of malignant peritoneal mesothelioma.